Hospital
Mercy Health-Allen Hospital LLC
Mercy Health-Allen Hospital LLC was paid $8.61M by Medicaid between Jan 2018 and Dec 2024, across 132 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoMERCY HEALTH-ALLEN HOSPITAL LLC
OBERLIN, OH 44074
OBERLIN, OH 44074
33aNPI1801825997assigned 07/01/2006
33bProvider typeCritical Access Hospital
28Total paid$8.61M
24GClaims215,971
24DCodes billed132
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#10 of 26
Median peer was paid$5.33M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,756 | $536K | |
| 2019 | 19,321 | $574K | |
| 2020 | 13,984 | $667K | |
| 2021 | 20,736 | $992K | |
| 2022 | 25,107 | $1.02M | |
| 2023 | 71,351 | $2.48M | |
| 2024incomplete | 47,716 | $2.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 23,914 | 21,883 | $2.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 13,707 | 11,538 | $1.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.1% | 4,203 | 3,396 | $615K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.5% | 1,457 | 977 | $556K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.6% | 4,470 | 4,278 | $479K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 935 | 682 | $329K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.3% | 826 | 612 | $282K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 860 | 691 | $269K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 1,307 | 853 | $233K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.6% | 1,054 | 833 | $135K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 6,150 | 5,243 | $133K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 1,451 | 354 | $100K |
120 more codes
| 80053 | Comprehensive metabolic panel | 1.1% | 12,507 | $96K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 461 | $91K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,791 | $30K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 134 | $28K |
| 80061 | Lipid panel | <1% | 1,140 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,540 | $20K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 71 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,498 | $16K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 524 | $16K |
| 84439 | <1% | 707 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,052 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 697 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,374 | $14K |
| 87070 | <1% | 669 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 527 | $12K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,177 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,944 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,075 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 160 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,571 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,478 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 36 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,569 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,155 | $6K |
| 82607 | <1% | 308 | $6K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 436 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 35 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 336 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,019 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 44 | $4K |
| 73030 | <1% | 346 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $4K |
| 83605 | <1% | 1,545 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 32 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 242 | $4K |
| 72110 | <1% | 219 | $4K | |
| 81001 | <1% | 7,226 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,902 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 83 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,341 | $3K |
| 76801 | <1% | 29 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,380 | $3K |
| 73630 | <1% | 509 | $3K | |
| 85027 | <1% | 392 | $3K | |
| 81003 | <1% | 3,190 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 335 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $3K |
| 73610 | <1% | 374 | $3K | |
| 84484 | <1% | 1,916 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 154 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 60 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 28 | $2K |
| 73564 | <1% | 157 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 100 | $2K |
| 83690 | <1% | 2,615 | $2K | |
| 84703 | <1% | 4,899 | $2K | |
| 83735 | <1% | 2,926 | $2K | |
| 73110 | <1% | 258 | $2K | |
| 73130 | <1% | 279 | $2K | |
| 97162 | <1% | 50 | $2K | |
| 87186 | <1% | 357 | $2K | |
| 86803 | <1% | 48 | $1K | |
| 82746 | <1% | 126 | $1K | |
| 87040 | <1% | 1,220 | $1K | |
| 93975 | <1% | 15 | $1K | |
| 87210 | <1% | 72 | $1K | |
| 80306 | <1% | 725 | $1K | |
| 96376 | <1% | 663 | $1K | |
| 86592 | <1% | 46 | $1K | |
| 87634 | <1% | 1,117 | $1K | |
| 90715 | <1% | 68 | $1K | |
| 85610 | <1% | 1,185 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $938.17 |
| 74018 | <1% | 243 | $883.54 | |
| 73560 | <1% | 57 | $687.67 | |
| 82728 | <1% | 28 | $678.78 | |
| 87420 | <1% | 24 | $671.06 | |
| 86403 | <1% | 896 | $626.12 | |
| 83880 | <1% | 314 | $572.14 | |
| 74022 | <1% | 103 | $568.55 | |
| 73502 | <1% | 29 | $554.89 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,569 | $504.50 |
| 82570 | <1% | 42 | $456.33 | |
| 86140 | <1% | 14 | $405.31 | |
| 84702 | <1% | 43 | $385.77 | |
| 83540 | <1% | 30 | $365.86 | |
| 82043 | <1% | 42 | $342.72 | |
| 82150 | <1% | 1,142 | $303.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,310 | $266.74 |
| 87077 | <1% | 83 | $259.13 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,386 | $244.02 |
| 83550 | <1% | 30 | $226.25 | |
| 80074 | <1% | 14 | $201.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,541 | $180.93 |
| 85379 | <1% | 463 | $163.80 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 74 | $122.87 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 129 | $121.93 |
| 72050 | <1% | 12 | $113.93 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,184 | $108.13 |
| 87808 | <1% | 32 | $96.96 | |
| 73140 | <1% | 12 | $91.02 | |
| 82077 | <1% | 226 | $80.69 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 318 | $75.44 |
| 87081 | <1% | 521 | $66.07 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 347 | $61.25 |
| 85730 | <1% | 87 | $37.88 | |
| 82550 | <1% | 17 | $37.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,436 | $35.73 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 524 | $34.18 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 851 | $32.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 814 | $29.31 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 725 | $26.57 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 212 | $20.28 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 23 | $4.35 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 18 | $2.47 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 189 | $0.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 52 | $0.48 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 50 | $0.00 |
| 94664 | 0% | 66 | $0.00 | |
| 87075 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (VP REIMBURSEMENT)
Parent organizationMERCY HEALTH LORAIN LLC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.